First, clinical data show a strong enrichment (83%) of the Her2-positive breast cancer in LFS women with p53 germline mutations, compared to 20–25% Her2 positivity in patients with sporadic breast cancer (50). The gene discussed is ERBB2; the disease is breast carcinoma.